TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ocumension Therapeutics ( (HK:1477) ) has shared an update.
Ocumension Therapeutics announced the cancellation and re-granting of options as part of its 2021 Share Option Scheme. The company canceled 4,018,842 options and re-granted 2,813,189 replacement options to 155 existing grantees, representing approximately 0.35% of the total shares. Additionally, Ocumension granted 15,462,865 new options and 8,952,185 awards to 430 grantees as further incentives, representing 1.90% and 1.10% of the total shares, respectively. This move aims to provide meaningful incentives and retain key personnel by aligning the exercise price with the prevailing market price of shares.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics is a company incorporated in the Cayman Islands, focusing on the healthcare industry. It specializes in developing therapeutic solutions and products, with a market focus on providing incentives and rewards to its employees and stakeholders through share option schemes.
Average Trading Volume: 7,023,089
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.62B
For an in-depth examination of 1477 stock, go to TipRanks’ Overview page.